<DOC>
	<DOCNO>NCT02270788</DOCNO>
	<brief_summary>PRIMARY OBJECTIVE : This pilot study characterize toxicity profile , determine maximum tolerate dose combination crenolanib sorafenib , determine feasibility administer drug patient relapse refractory hematologic malignancy , include acute myeloid leukemia ( AML ) , AML prior myelodysplastic syndrome ( MDS ) , myeloperoxidase ( MPO ) -positive mixed phenotype acute leukemia FLT3-internal tandem duplication ( ITD ) tyrosine kinase domain ( TKD ) mutation . The study include two phase : - The dose-escalation phase characterize dose-limiting toxicity ( DLTs ) determine maximum tolerate dose ( MTD ) recommend phase 2 dose ( RP2D ) crenolanib give combination sorafenib . - The dose-expansion cohort ass safety explore efficacy combination .</brief_summary>
	<brief_title>Crenolanib Combination With Sorafenib Patients With Refractory Relapsed Hematologic Malignancies</brief_title>
	<detailed_description>Each course therapy 28 day ( ±5 day ) , unless disease progression see combination crenolanib sorafenib . Patients may receive subsequent course ( total 365 day ) disease progression unacceptable toxicity . In Day 1 Course 1 , crenolanib give morning follow characterization pharmacokinetic profile follow 24-hour period . Starting day 2 Course 1 , crenolanib give 3 time per day day 28 . On Days 8 28 Course 1 , sorafenib give per day . Inter-patient dose escalation de-escalation crenolanib perform base tolerability toxicity . Response assess day 8 end course . If disease progress prior day 8 , sorafenib give day 8 . In subsequent course ( 365 day ) , crenolanib sorafenib give day 1 28 . The treat physician may increase decrease sorafenib dose frequency administration per trial 's dose table basis effect tolerability . If necessary , crenolanib dose decrease per protocol . Maintenance therapy must start sooner 30 day later 120 day hematopoietic stem cell therapy ( HSCT ) . Single agent crenolanib start last dose tolerate prior HSCT . Crenolanib maintenance give 365 day additional therapy provide discussion discussion PI , patient continue benefit 1 year .</detailed_description>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Crenolanib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Inclusion Criteria Initial Enrollment : Participant relapse refractory hematologic malignancy ( measurable disease ) FLT3ITD TKD mutation one follow diagnosis : Acute myeloid leukemia ( AML ) AML prior myelodysplastic syndrome ( MDS ) Myeloperoxidase ( MPO ) positive mixed phenotype acute leukemia Participant 's disease relapse , refractory induction and/or salvage therapy , relapse hematopoietic stem cell transplant ( HSCT ) . Participant disease test positive FLT3ITD TKD within 60day screening period . Participant 's age 1 25 year , inclusive ( St. Jude participant must age 1 25 year , inclusive ) . Karnofsky Lansky performance score &gt; 60 % . The Lansky performance score use participant &lt; 16 year Karnofsky performance score participant ≥ 16 year . Adequate organ function define : Bilirubin ≤1.5 x upper limit normal ( ULN ) ALT ≤ 3 x ULN AST ≤ 3 x ULN Serum creatinine ≤1.5 x ULN Participant must recover acute side effect prior anticancer therapy , : At least 2 week elapse since prior systemic cytotoxic chemotherapy ( except intrathecal chemotherapy , hydroxyurea , lowdose cytarabine , and/or low dose maintenance therapy vincristine , mercaptopurine , methotrexate glucocorticoid ) , If participant receive prior allogeneic HSCT , least 30 day elapse evidence clinically significant graft versus host disease require treatment and/or &gt; grade 2 persistent nonhematologic toxicity relate transplant Exclusion Criteria Initial Enrollment : Concurrent chemotherapy , targeted anticancer agent , hydroxyurea , lowdose cytarabine , intrathecal therapy and/or low dose maintenance therapy vincristine , mercaptopurine , methotrexate glucocorticoid . Patient concurrent severe and/or uncontrolled medical condition , opinion investigator , may impair participation study evaluation safety and/or efficacy . Known HIV infection active hepatitis B ( define hepatitis B surface antigenpositive ) C ( define hepatitis C antibodypositive ) . Prior crenolanib treatment nonleukemic indication . Major surgical procedure within 14 day Day 1 administration crenolanib . Pregnant lactating ( female participant childbearing potential must negative serum urine pregnancy test require within 7 day prior start treatment ) . Male female participant reproductive potential must agree use appropriate method contraception duration study treatment least 30 day last dose protocol treatment Inability unwillingness research participant legal guardian/representative give write informed consent . Inclusion Criteria Maintenance Therapy After HSCT : Patient must receive crenolanib protocol prior HSCT continue maintenance . Patient must within 30 120 day hematopoietic stem cell transplant ( HSCT ) . Response previous treatment protocol : least resistant disease clinical benefit well response . Patient stable dose immunosuppressive drug management prophylaxis graftversushostdisease ( GVHD ) ( define escalation therapy GVHD ) within 14 day prior start crenolanib . Patient must recover acute side effect HSCT , define &lt; Grade 2 nonhematological toxicity relate transplant ( exception alopecia nonacute toxicity ) . Adequate hematopoietic recovery ( ANC &gt; 500/mm^3 platelet count &gt; 50,000/mm^3 ) Research participant legal guardian/representative able willing give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>